{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:32:41Z","timestamp":1792715561174,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020044","name":"Yale School of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lungcan.2025.108749","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:17:13Z","timestamp":1758057433000},"page":"108749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-6962","authenticated-orcid":false,"given":"Meng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-3907","authenticated-orcid":false,"given":"Jeffrey P.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108749_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108421","article-title":"Real-world outcomes of non-small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations","volume":"201","author":"Shahnam","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108749_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108596","article-title":"Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes","volume":"205","author":"Abolfathi","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108749_b0015","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/0008-5472.CAN-22-1508","article-title":"Estimation of neutral mutation rates and quantification of somatic variant selection using cancereffectsizeR","volume":"83","author":"Mandell","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108749_b0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2021.10.008","article-title":"Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors-on average-to exhibit a lower mutation burden","volume":"166","author":"Tan","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108749_b0025","unstructured":"lungcancer_SBS4_TMB_IO, Github, n.d. https:\/\/github.com\/Townsend-Lab-Yale\/lungcancer_SBS4_TMB_IO (accessed May 29, 2025)."},{"key":"10.1016\/j.lungcan.2025.108749_b0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2025.108749_b0040","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2025.108749_b0035","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2025.108749_b0045","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2025.108749_b0050","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108749_b0055","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2025.108749_b0060","doi-asserted-by":"crossref","first-page":"346","DOI":"10.21037\/tlcr-22-639","article-title":"Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review","volume":"12","author":"Santarpia","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108749_b0065","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1158\/0008-5472.CAN-20-3991","article-title":"Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108749_b0070","doi-asserted-by":"crossref","DOI":"10.1093\/molbev\/msac084","article-title":"Attribution of cancer origins to endogenous, exogenous, and preventable mutational processes","volume":"39","author":"Cannataro","year":"2022","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.lungcan.2025.108749_b0075","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jtho.2022.11.030","article-title":"Tobacco smoking-related mutational signatures in classifying smoking-associated and nonsmoking-associated NSCLC","volume":"18","author":"Ernst","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108749_b0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"\u0141uksza","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2025.108749_b0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","article-title":"Lineage tracking reveals dynamic relationships of T cells in colorectal cancer","volume":"564","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2025.108749_b0090","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2025.108749_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076710","article-title":"The efficacy of tumor mutation burden as a biomarker of response to immune checkpoint inhibitors","volume":"24","author":"Moeckel","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2025.108749_b0100","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108749_b0105","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108749_b0110","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 investigators, pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108749_b0115","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"KEYNOTE-042 investigators, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:44:55Z","timestamp":1762490695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"alternative-id":["S0169500225006415"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108749","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108749"}}